Neurocrine (NBIX) Biosciences announced the appointment of Sanjay Keswani, M.D., to the company’s executive management team as Chief Medical Officer, effective June 2. Dr. Keswani, an accomplished physician-scientist who has more than 20 years of pharmaceutical industry experience with broad R&D expertise in multiple therapeutic areas, will lead the clinical development and medical affairs activities at Neurocrine. Dr. Keswani succeeds Eiry W. Roberts, M.D., who has served as CMO for the past seven years and who will remain with Neurocrine in a strategic advisory role.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target lowered to $137 from $154 at UBS
- Neurocrine’s Strong Market Position and Growth Potential Justify Buy Rating Amid Challenges
- Neurocrine price target raised to $184 from $183 at JPMorgan
- Neurocrine’s ingrezza shows efficacy in tardive dyskinesia study
- Neurocrine presents new KINECT-HD data